3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Motor Activity
1
Head and Neck Neoplasms
1
Fatigue
1
Esophageal Neoplasms
1
Carcinoma, Bronchogenic
1
Brain Neoplasms
1
Interventions
Docetaxel
5
pembrolizumab
4
Radiotherapy
3
ulixertinib
2
Trastuzumab
2
Paclitaxel
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Erlotinib Hydrochloride
2
Carboplatin
2
Capecitabine
2
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
regorafenib
1
pertuzumab
1
palbociclib
1
osimertinib
1
oncogene protein E7, Human papillomavirus type 16
1
omipalisib
1
oblimersen
1
motexafin gadolinium
1
larotrectinib
1
ipatasertib
1
fludarabine
1
erdafitinib
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Exercise Therapy
×
CNS
×
Clear all
NCT04517019
2020-08-18
OnkoFit II
University Hospital Tuebingen
Phase NA
Unknown
201 enrolled